Team

Dragonfleye benefits from the experience and expertise of its multidisciplinary management team. The diverse backgrounds of this group together possess all the skill sets required to take a novel idea from concept to commercialization
Rajeev Muni, MD
CEO & Co-founder

• Vitreoretinal surgeon at St. Michael’s Hospital, The Hospital for Sick Children and Kensington Eye Institute • Associate Professor and Chair of Clinical Research in the Department of Ophthalmology and Vision Sciences, University of Toronto • 150+ peer-reviewed publications in top academic journals • MD, McMaster University; pediatric vitreoretinal surgery fellowship, University of Southern California; M.A. clinical epidemiology, Harvard School of Public Health

Allan Silber, B.Sc
Executive Chairman & Co-founder

• Distinguished business leader with extensive experience in corporate finance, private equity and venture capital • Senior management and board of director roles at biotech, financial services and real estate companies • Co-founder and former Executive Chairman of a radiotherapeutic company • Chairman of the Board of Verity Pharmaceuticals, a Canadian privately owned and operated specialty pharmaceutical company

Radha Kohly, MD, PhD
Head of Strategy and Corporate Development & Co-Founder

• Medical Retina Specialist and Cataract surgeon, Sunnybrook Health Sciences Centre • Assistant Professor, Department of Ophthalmology & Vision Sciences, University of Toronto • Expertise in diagnosis and management of inherited retinal diseases • PhD, York University; MD, McMaster University; Medical Retina fellow, Moorfields Eye Hospital, UK

Aaron Weinroth, M.A.Sc
Chief Operating Officer

• Over 26 years experience creating and commercializing new medical devices and technologies • Medtech leader, advisor, mentor, reviewer, and consultant • Senior business and engineering roles in fields including neurotechnology, ophthalmology, surgical navigation, imaging, and optics • Strategy and execution oversight for market analysis, product roadmap and definition, intellectual property, health economics and reimbursement, regulatory affairs, business development, and market introduction • Electrical and biomedical engineering degrees, University of Toronto •  Licensed Professional Engineer

Jerry Rosenblatt, PhD
Chief Business Officer

• Founder and CEO of Rosenblatt Life Science Consultants • 30+ years assisting pharmaceutical companies with financial forecasting, opportunities assessment and business valuations • Former Head of the Global Forecasting & Opportunity Assessment consulting group, IMS Health (now IQVIA) • MBA and PhD, marketing science, Concordia University • PMSA Lifetime Achievement Award

Ike Ahmed, MD
Head of Glaucoma Platform

• Chair and professor, Department of Ophthalmology and Visual Sciences, University of Utah • Senior clinical, educational and innovation roles at the Prism Eye Institute; University of Toronto; Trillium Health Hospital Network; Center for Glaucoma Innovation, University of Utah • Global leader in complex eye surgery • Designed various instruments and implants for cataract, iris reconstruction, and glaucoma surgeries • Consultant to manufacturers developing new medical devices and technologies • MD, University of Toronto

Emma Rutherford, MS
Lead Engineer

• B.S. in Mechanical Engineering and Physics, and M.S. in Mechanical Engineering from the Massachusetts Institute of Technology (MIT) • PhD candidate in Mechanical Engineering department at MIT with a focus on Mechanical Design

Glenn Noronha, PhD
Head of Clinical Development

• Drug, device, and combination product expert with 25 years of experience leading R&D teams, resulting in 3 ophthalmic drug approvals • Extensive expertise with strategy, planning and executing all stages of drug development that targets ocular diseases, including working with clinical, regulatory, scientific, non-clinical, and technical and product development areas • Senior leadership experience with biotechnology and pharmaceutical companies, including PYC Therapeutics, BridgeBio Pharma, Clearside Biomedical and Alcon (formerly a subsidiary of Novartis) • PhD, Loyola University Chicago; post-doctoral research, University of California, Irvine

Mark Hedgeland, MS
Director of Technical Operations

• Dynamic biotech leader with a track record of advancing technologies from early-stage growth through acquisition • Deep expertise in ophthalmic drug delivery innovation, combination products, regulatory strategy, and cross-functional program execution • Proven ability to develop teams, forge strategic partnerships, and align development with strategic objectives in complex, regulated environments • Experience includes development leadership roles at Genentech, Novartis, Gyroscope Therapeutics, and Orbit Biomedical • MS in Mechanical Engineering from Clarkson University and BS in Biomedical Engineering from Bucknell University